Theriva Biologics, Inc. — 2019 Q2 filing summary
Filing identity: The supplied filing is Synthetic Biologics, Inc.’s Form 10-Q for the quarter ended June 30, 2019, not a filing under the name Theriva Biologics, Inc. The summary below reflects the filing text provided.
Business context and reporting period
Synthetic Biologics described itself as a clinical-stage microbiome therapeutics company. Its lead programs were SYN-004 (ribaxamase), SYN-010 for IBS-C, and early-stage SYN-020. The unaudited report covers the three and six months ended June 30, 2019, with comparisons to 2018.
Financial performance and position
| Metric | 2019 | Comparable 2018 / prior date |
|---|---|---|
| Revenue | No revenue reported in the presented statements | No revenue reported in the presented statements |
| Operating expenses, three months | $3.64 million | $5.00 million |
| Net loss, three months | $3.56 million | $4.21 million |
| Net loss attributable to common stockholders, three months | $3.71 million; $0.23 per share | $4.26 million; $1.16 per share |
| Operating expenses, six months | $7.21 million | $9.99 million |
| Net loss, six months | $7.09 million | $6.54 million |
| Net loss attributable to common stockholders, six months | $7.68 million; $0.48 per share | $6.63 million; $1.80 per share |
| Operating cash used, six months | $7.21 million | $10.39 million |
| Cash and cash equivalents | $21.71 million at June 30, 2019 | $28.92 million at December 31, 2018 |
| Total liabilities | $4.41 million, including $0.83 million of lease liabilities | $3.69 million |
All figures are in U.S. dollars. Gross margins are not meaningful because the filing reports no revenue. Cash declined by $7.21 million in the first half; there were no investing cash flows or financing proceeds during that period. The company reported an accumulated deficit of $227.14 million. Its balance sheet showed $23.01 million in current assets and $3.81 million in current liabilities.
Changes versus prior comparable periods
- Second-quarter operating expenses fell 27% year over year, with lower general and administrative and research and development costs. Management cited reduced stock-based compensation, consulting and investor-relations costs, restructuring-related payroll reductions, and no SYN-004 clinical-trial activity during the quarter; increased SYN-020 manufacturing costs partly offset the decline.
- Six-month operating expenses also fell 28%, but common-stockholder net loss increased year over year, partly because 2018 included substantial noncash warrant fair-value income that did not recur in 2019.
- Weighted-average shares were materially higher than in 2018, reflecting the company’s changed capital structure; per-share comparisons are also affected by the August 2018 1-for-35 reverse split.
- The company adopted lease accounting guidance in January 2019 and recorded a right-of-use asset and lease liability.
Outlook, risks, contingencies and unusual items
- Management said cash available in early August 2019 was approximately $20.1 million and expected to fund planned operations through at least the end of Q3 2020. This is a forward-looking estimate, not a guarantee; the filing also warns that later-stage trials require additional funding.
- The proposed SYN-004 Phase 3 program for CDI was expected to cost more than $80 million, and management said it would pursue a strategic partner or other financing before starting it. No committed third-party financing was disclosed.
- Management anticipated a SYN-010 Phase 2b data readout in the first half of 2020; enrollment had been extended due to higher-than-expected screening failures. The company anticipated filing a SYN-020 IND in Q1 2020.
- After quarter-end, the company signed an agreement for a Washington University SYN-004 Phase 1b/2a study in up to 36 allogeneic HCT recipients, estimated to cost approximately $3.2 million. Enrollment was expected in Q1 2020, subject to FDA and institutional review board approval.
- Potential financing risks include dilution from equity issuance, restrictions on ATM sales, and the possibility that development programs may be delayed, curtailed or stopped if funding is unavailable. The company said its ATM had up to $19.9 million remaining subject to conditions, and it had made no ATM sales in 2019 through the report date.
- The company had 18.9 million warrants outstanding at June 30, 2019, including 18.0 million exercisable at $1.38 per share. Conversion of Series B preferred stock also generated deemed dividends: $515,000 in the first half of 2019, reducing income attributable to common stockholders without representing a cash operating expense.
- No material litigation or off-balance-sheet arrangements were reported. Management concluded disclosure controls and procedures were effective as of June 30, 2019.
Important facts for investors to verify
- Confirm the issuer and filing identity: the supplied document names Synthetic Biologics, Inc., despite the request identifying Theriva Biologics, Inc.
- Review subsequent cash balances, actual cash burn, and whether financing or a strategic partnership was secured; the stated runway was management’s estimate.
- Track trial approvals, enrollment and results for SYN-004, SYN-010 and SYN-020, as well as actual spending against expected study costs.
- Assess potential dilution from outstanding warrants, Series B preferred conversions, and any future ATM or other securities offerings.
- Reconcile quarterly and year-to-date cash-use disclosures: the cash-flow statement reports $7.21 million used in operations for six months, while the risk-factor discussion separately gives quarterly and year-to-date figures that are not fully consistent with that presentation.